ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2020
Frequency-Specific Optogenetic Deep Brain Stimulation of Subthalamic Nucleus Improves Parkinsonian Motor Behaviors.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Deep Brain Stimulation of the Habenula: Systematic Review of the Literature and Clinical Trial Registries.Frontiers in psychiatry · 2021Pooled it
- Deep Brain Stimulation of the Subthalamic Nucleus Modulates Reward-Related Behavior: A Systematic Review.Frontiers in human neuroscience · 2020Pooled it
- Distinct contributions of two subpopulations of subthalamic neurons to levodopa-induced dyskinesia.Science advances · 2026Article
- Deep brain stimulation alleviates Parkinsonian motor deficits through desynchronizing GABA release in mice.Nature communications · 2025Article
- Flexible graphene-based neurotechnology for high-precision deep brain mapping and neuromodulation in Parkinsonian rats.Nature communications · 2025Article
- Pallidothalamic Circuit-Selective Manipulation Ameliorates Motor Symptoms in a Rat Model of Parkinsonian.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Regulatory aspects of optogenetic research and therapy for retinitis pigmentosa under EU law.Frontiers in medical technology · 2025Review
- A framework for translational therapy development in deep brain stimulation.NPJ Parkinson's disease · 2024Review
- Unraveling the Complexity of Parkinson's Disease: Insights into Pathogenesis and Precision Interventions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Human TRPV1 is an efficient thermogenetic actuator for chronic neuromodulation.Cellular and molecular life sciences : CMLS · 2024Article
- A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease.NPJ Parkinson's disease · 2024Review
- Bidirectional regulation of motor circuits using magnetogenetic gene therapy.Science advances · 2024Article
- Review
- Irregular optogenetic stimulation waveforms can induce naturalistic patterns of hippocampal spectral activity.Journal of neural engineering · 2024Article
- Aerobic exercise improves depressive symptoms in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.IBRO neuroscience reports · 2024Article
- Article
- A longitudinal electrophysiological and behavior dataset for PD rat in response to deep brain stimulation.Scientific data · 2024Article
- Bidirectional Regulation of Motor Circuits Using Magnetogenetic Gene Therapy Short: Magnetogenetic Regulation of Motor Circuits.bioRxiv : the preprint server for biology · 2024Article
- Non-Faradaic optoelectrodes for safe electrical neuromodulation.Nature communications · 2024Article
- Focused stimulation of dorsal versus ventral subthalamic nucleus enhances action-outcome learning in patients with Parkinson's disease.Brain communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective therapy for the motor symptoms of Parkinson's disease (PD). However, the neural elements mediating symptom relief are unclear. A previous study concluded that direct optogenetic activation of STN neurons was neither necessary nor sufficient for relief of parkinsonian symptoms. However, the kinetics of the channelrhodopsin-2 (ChR2) used for cell-specific activation are too slow to follow the high rates required for effective DBS, and thus the contribution of activation of STN neurons to the therapeutic effects of DBS remains unclear. We quantified the behavioral and neuronal effects of optogenetic STN DBS in female rats following unilateral 6-hydroxydopamine (6-OHDA) lesion using an ultrafast opsin (Chronos). Optogenetic STN DBS at 130 pulses per second (pps) reduced pathologic circling and ameliorated deficits in forelimb stepping similarly to electrical DBS, while optogenetic STN DBS with ChR2 did not produce behavioral effects. As with electrical DBS, optogenetic STN DBS exhibited a strong dependence on stimulation rate; high rates produced symptom relief while low rates were ineffective. High-rate optogenetic DBS generated both increases and decreases in firing rates of single neurons in STN, globus pallidus externa (GPe), and substantia nigra pars reticular (SNr), and disrupted β band oscillatory activity in STN and SNr. High-rate optogenetic STN DBS can indeed ameliorate parkinsonian motor symptoms through reduction of abnormal oscillatory activity in the STN-associated neural circuit, and these results highlight that the kinetic properties of opsins have a strong influence on the effects of optogenetic stimulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.